Last reviewed · How we verify
Brimo PS DDS®
Brimo PS DDS is a testosterone replacement therapy.
Brimo PS DDS is a testosterone replacement therapy. Used for Treatment of hypogonadism in adult males.
At a glance
| Generic name | Brimo PS DDS® |
|---|---|
| Sponsor | Allergan |
| Drug class | Testosterone replacement therapy |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 2 |
Mechanism of action
It works by releasing testosterone into the body through a subcutaneous implant, mimicking the body's natural production of testosterone. This helps to alleviate symptoms of hypogonadism, such as low libido and fatigue.
Approved indications
- Treatment of hypogonadism in adult males
Common side effects
- Acne
- Erythrocytosis
- Sleep apnea
- Prostate enlargement
- Testicular atrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimo PS DDS® CI brief — competitive landscape report
- Brimo PS DDS® updates RSS · CI watch RSS
- Allergan portfolio CI